Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens
In late December, the ACR convened a COVID-19 Vaccine Consortium via a conference call to consider rheumatology’s place in the massive worldwide effort to develop, test, deliver and further study the vaccines promising to bring the historic pandemic under control.
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
An analysis of data from the COVID-19 Global Rheumatology Alliance registry shows that use of disease-modifying antirheumatic drugs or non-steroidal anti-inflammatory drugs did not increase the risk of hospitalization for COVID-19 patients with rheumatic disease, but steroid use did.
Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow below.